Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash from Operations (2021 - 2025)

Historic Cash from Operations for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$7.4 million.

  • Lyra Therapeutics' Cash from Operations rose 5462.61% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.1 million, marking a year-over-year increase of 5606.5%. This contributed to the annual value of -$70.0 million for FY2024, which is 1059.49% down from last year.
  • Latest data reveals that Lyra Therapeutics reported Cash from Operations of -$7.4 million as of Q3 2025, which was up 5462.61% from -$6.6 million recorded in Q2 2025.
  • Lyra Therapeutics' Cash from Operations' 5-year high stood at $3.4 million during Q2 2021, with a 5-year trough of -$22.5 million in Q1 2024.
  • In the last 5 years, Lyra Therapeutics' Cash from Operations had a median value of -$11.4 million in 2024 and averaged -$11.9 million.
  • In the last 5 years, Lyra Therapeutics' Cash from Operations crashed by 35051.76% in 2022 and then surged by 6701.87% in 2025.
  • Over the past 5 years, Lyra Therapeutics' Cash from Operations (Quarter) stood at -$11.3 million in 2021, then fell by 7.67% to -$12.2 million in 2022, then crashed by 56.68% to -$19.1 million in 2023, then soared by 40.43% to -$11.4 million in 2024, then soared by 35.16% to -$7.4 million in 2025.
  • Its last three reported values are -$7.4 million in Q3 2025, -$6.6 million for Q2 2025, and -$8.8 million during Q1 2025.